Testosterone, testosterone therapy and prostate cancer

References

• Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013a;217:R25–R45.
   Google Scholar
• Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013b;217:R47–R71.
   Web of Science ®Google Scholar
• Traish A. Testosterone therapy in men with testosterone deficiency: are we beyond the point of no return?. Investig Clin Urol. 2016;57:384–400.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297.
   Google Scholar
• Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II. Arch Surg. 1941;43:209–223.
   Google Scholar
• Prout GR, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967;20:1871–1878.
   PubMed Web of Science ®Google Scholar
• Fowler JE, Whitmore WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372–375. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7277602.
   PubMed Web of Science ®Google Scholar
• Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128:492–497.
   PubMed Web of Science ®Google Scholar
• Stamey T, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 1990;144:1479–1480.
   PubMed Web of Science ®Google Scholar
• Bubley GJ. Is the flare phenomenon clinically significant?. Urol. 2001;58:5–9.
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Investig Med. 1982;5:267–275.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–424.
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 2004;10:409–419.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Bruning C, DeWolf W. Occult prostate cancer in men with low serum testosterone levels. Jama. 1996;276:1904–1906.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–321.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Garland C, McPhillips JB, et al. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 1990;50:169–173.
   PubMed Web of Science ®Google Scholar
• Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2:27–32.
   PubMed Web of Science ®Google Scholar
• Nomura AM, Stemmermann GN, Chyou PH, et al. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:621 LP–625. Available at: http://cebp.aacrjournals.org/content/5/8/621.abstract.
   Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–1126.
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case- control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6:967–969.
   PubMed Web of Science ®Google Scholar
• Dorgan JF, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7:1069–1074. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9865423.
   PubMed Web of Science ®Google Scholar
• Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2003;12:1410–1416.
   PubMed Web of Science ®Google Scholar
• Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–1675.
   PubMed Web of Science ®Google Scholar
• Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004;95:65–71.
   PubMed Web of Science ®Google Scholar
• Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108:418–424.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Carter HB, Platz E. a, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14:2257–2260.
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005;14:1262–1269.
   PubMed Web of Science ®Google Scholar
• Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005;47:308–312.
   PubMed Web of Science ®Google Scholar
• Severi G, Morris H. a, MacInnis RJ, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:86–91.
   PubMed Web of Science ®Google Scholar
• Karamanolakis D, Lambou T, Bogdanos J, et al. Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (≥3.0 and <10.0 ng/ml). Anticancer Res. 2006;26:3159–3166.
   PubMed Web of Science ®Google Scholar
• Travis RC, Key TJ, Allen NE, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;121:1331–1338.
   PubMed Web of Science ®Google Scholar
• Yano M, Imamoto T, Suzuki H, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007;51:375–380.
   PubMed Web of Science ®Google Scholar
• Lane BR, Stephenson AJ, Magi-Galluzzi C, et al. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urol. 2008;72:1240–1245.
   PubMed Web of Science ®Google Scholar
• Daniels NA, Nielson CM, Hoffman AR, et al. Sex hormones and the risk of incident prostate cancer. Urol. 2010;76:1034–1040.
   PubMedGoogle Scholar
• Gill JK, Wilkens LR, Pollak MN, et al. Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort. Prostate. 2010;70:906–915.
   PubMed Web of Science ®Google Scholar
• Salonia A, Gallina A, Briganti A, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117:3953–3962.
   PubMed Web of Science ®Google Scholar
• Muller RL, Gerber L, Moreira DM, et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62:757–764.
   PubMed Web of Science ®Google Scholar
• Mearini L, Zucchi A, Nunzi E, et al. Low serum testosterone levels are predictive of prostate cancer. World J Urol. 2013;31:247–252.
   PubMed Web of Science ®Google Scholar
• Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma. Longitudinal Study Cancer. 1999;86:312–315.
   Google Scholar
• Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. Jco. 2000;18:847–853.
   PubMed Web of Science ®Google Scholar
• Shin BS, Hwang EC, Im CM, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men. Korean J Urol. 2010;51:819–823.
   PubMedGoogle Scholar
• Salonia A, Abdollah F, Capitanio U, et al. Serum sex steroids depict a nonlinear U-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res. 2012;18:3648–3657.
   PubMed Web of Science ®Google Scholar
• Porcaro AB, Petrozziello A, Ghimenton C, et al. Associations of pretreatment serum total testosterone measurements with pathology-detected gleason score cancer. Urol Int. 2014;93:269–278.
   PubMed Web of Science ®Google Scholar
• Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J. 2001;48:573–578.
   PubMed Web of Science ®Google Scholar
• Isom-Batz G, Bianco FJ, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935–1937.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urol. 2006;68:1263–1267.
   PubMed Web of Science ®Google Scholar
• Mearini L, Costantini E, Zucchi A, et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int. 2008;80:134–140.
   PubMed Web of Science ®Google Scholar
• Ahmadi H, Allameh F, Baradaran N, et al. Circulating sex hormones play no role in the association between sexual activity and the risk of prostate cancer. J Sex Med. 2011;8:905–913.
   PubMed Web of Science ®Google Scholar
• Botto H, Neuzillet Y, Lebret T, et al. High incidence of predominant gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol. 2011;186:1400–1405.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim BH, Park CH, et al. Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol. 2012;53:9–13.
   PubMedGoogle Scholar
• Cui Y, Zong H, Yan H, et al. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:132–143.
   PubMed Web of Science ®Google Scholar
• Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731–741.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F. Testosterone treatment in hypogonadal patients does not cause higher incidence of prostate cancer. J Urol. 2008;179:301.
   Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow-up of 3 registries. J Urol. 2015;193:80–86.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–922.
   PubMed Web of Science ®Google Scholar
• Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–536.
   PubMed Web of Science ®Google Scholar
• Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165–1170.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639–644.
   PubMed Web of Science ®Google Scholar
• Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–541.
   PubMed Web of Science ®Google Scholar
• Balbontin FG, Moreno SA, Bley E, et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014;114:125–130.
   PubMed Web of Science ®Google Scholar
• Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62–64.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Khanna A, Badhiwala N, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015;194:1271–1276.
   PubMed Web of Science ®Google Scholar
• Kaplan AL, Trinh Q, Sun M, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014;11:1063–1070.
   PubMed Web of Science ®Google Scholar
• Kaplan AL, Lenis AT, Shah A, et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med. 2015;12:374–380.
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol. 2005;60:1451–1457.
   Google Scholar
• Shabsigh R, Crawford ED, Nehra A, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21:9–23.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185:1256–1260.
   PubMedGoogle Scholar
• Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011;107:1369–1373.
   PubMed Web of Science ®Google Scholar
• San Francisco IF, Rojas PA, Dewolf WC, et al. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014;114:229–235.
   PubMed Web of Science ®Google Scholar
• Ory J, Flannigan R, Lundeen C, et al. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196:1082–1089.
   PubMed Web of Science ®Google Scholar
• Kacker R, Hult M, San Francisco IF, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18:16–20.
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–2351.
   PubMed Web of Science ®Google Scholar
• Røder MA, Christensen IJ, Berg KD, et al. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int. 2012;109:520–524.
   PubMed Web of Science ®Google Scholar
• Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl. 2014;16:864–868.
   PubMed Web of Science ®Google Scholar
• Chuu CP, Hiipakka RA, Fukuchi J, et al. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65:2082–2084.
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010;70:1600–1607.
   PubMed Web of Science ®Google Scholar
• Isaacs JT, D'Antonio JM, Chen S, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012;72:1491–1505.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Antonarakis ES, Wang H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2–269ra2.
   PubMed Web of Science ®Google Scholar
• Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7:e015284.
   PubMed Web of Science ®Google Scholar
• Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
   PubMed Web of Science ®Google Scholar
• Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metabol. 2010;95:2560–2575.
   PubMed Web of Science ®Google Scholar
• Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:211.
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–1351.
   PubMed Web of Science ®Google Scholar
• Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol. 2016;85:436–443.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Haider KS, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251–261.
   PubMed Web of Science ®Google Scholar
• Haider A, Haider KS, Doros G, et al. Long-term testosterone therapy improves blood pressure and lipid profiles in hypogonadal men-results from a propensity-matched subgroup of a controlled registry study. Endocr Rev. 2017;38. Available at: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617152968.
   Google Scholar
• Saad F, Yassin A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes. 2016;40:162–170.
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11:1567–1576.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes. 2016;40:162–170.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang X, Zhong Y, et al. Dynamic patterns of testosterone levels within individuals and risk of prostate cancer among hypogonadal men: a longitudinal study. J Urol. 2018;199:465–473.
   PubMed Web of Science ®Google Scholar
• Yassin A, Salman M, Talib RA, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20:125–133.
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Pearlman AM, Godoy G, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25:24–28.
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, et al. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clin Endocrinol. 2016;84:107–114.
   PubMed Web of Science ®Google Scholar